ASTON Sci. Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ASTON Sci. Inc. - overview
Established
2018
Location
Hanam, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2018, and based in Seoul, South Korea, ASTON Sci. Inc. operates as a biopharmaceutical company that develops oncology, immunology, and geriatrics-related medicines. The company was founded by its Chief Executive Officer Hun Jung, Chief Executive Officer and Chief Business Officer Harry Hunwoo Shin, Jihyun Kim, Cwangkwang Chung, and Ilboo Kim.
In May 2026, ASTON Sci. Inc. raised KRW 17 billion in pre-IPO funding from unspecified investors. ASTON Sci conducts research, performs clinical development, and creates therapeutic medicine and vaccines for treating cancer.
The company has ten clinical and preclinical pathways as of 2022, including two cancer therapeutic vaccines known as AST-301 and AST-021p. The Ministry of Food and Drug Safety is reviewing AST-301 for clinical trials, while AST-021p is in phase 1 clinical trial for advanced solid tumors. By 2030, the company plans to extend its pipeline to 15 medications across four therapeutic domains, focusing on the efficient development of novel drugs with high unmet medical needs and clinical demand. By early 2023, the company also intends to list on the KOSDAQ in order to assist its clinical and business development.
Current Investors
G.N.TECH Venture Capital, Mirae Asset Venture Investment, NAU IB Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.astonsci.com
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
ASTON Sci. Inc. - timeline of key events
ASTON Sci. Inc. - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue (USD) | 211,056,700 | 60,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | (71.6%) | - | - | - |
| EBITDA (USD) | (7,430,236,209) | (14,926,371,020) | - | - | - |
| Operating Income (USD) | (7,997,698,209) | (16,249,733,020) | - | - | - |
| Operating Margin | (3789.4%) | (27082.9%) | - | - | - |
| % EBITDA Margin | (3520.5%) | (24877.3%) | - | - | - |
| NET Income (USD) | (17,838,446,832) | (25,561,460,091) | - | - | - |
| % Net Margin | (8452.0%) | (42602.4%) | - | - | - |
ASTON Sci. Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.